Pluristem CEO and Chairman, Mr. Zami Aberman commented, "We are receiving more attention from the scientific community as our research and development team continues to successfully show how innovative our Placenta eXpanded (PLX) cells are. These PLX cells are mesenchymal stem cells expanded in our proprietary 3D PluriX(TM) Bioreactor System."
Pluristem's presentations are entitled, "Expansions of cord blood (CB) derived unseparated hematopoietic stem cells (HSC) co-cultured with mesenchymal cells growing in three dimensional (3-D) mode" and "Promotion of CD34+ cells engraftment using mesenchymal stromal cells expanded ex vivo in bioreactor containing high-density 3-D culture."
Pluristem will also attend the 2007 BIO International Convention being held at the Boston Convention & Exhibition Center from May 6-9, 2007. BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations.
Mr. Aberman added, "These venues provide us with several opportunities to interact with researchers, laboratory professional, physicians, regulatory specialists, business leaders, investments professionals and business colleagues, all working or interested in the cellular therapy sector."
Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB).
Pluristem's products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.
Pluristem has offices in the USA with research and manufacturing facilities in Israel.
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT); that future Pluristems products will participate in the approximate $30 billion therapeutic and regenerative cellular market. Factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees wh ose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
Pluristem Life Systems
William Prather, 303-883-4954
Sr. VP Corporate Development
Strategic Growth International, Inc.
Richard Cooper, 212-838-1444
Miri Segal, 212-838-1444
Jennifer Zimmons, 212-838-1444
Segue Ventures LLC
Craig Bird, 215-885â??4981
Investorsâ?? Message Board: